Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib in MET+ Advanced HCC
NCT02115373Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib in hepatocellular carcinoma (HCC), sponsored by Merck KGaA. Started May 2014; status: completed.
02
Drugs
tepotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02115373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115373.